01:15 , Dec 22, 2018 |  BioCentury  |  Product Development

A year of digital progress at Novartis

Novartis AG Chief Digital Officer Bertrand Bodson is capping off his inaugural year with the pharma’s first approval of a digital therapeutic and 10 deals under his belt to integrate new technologies throughout the company....
03:53 , Sep 21, 2018 |  BC Innovations  |  Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
21:09 , May 1, 2018 |  BC Innovations  |  Translation in Brief

Rewriting cancer’s origin story

A collection of 29 papers published across a suite of Cell journals in April by The Cancer Genome Atlas (TCGA) consortium completed the Pan-Cancer Atlas -- a comprehensive analysis of molecular signatures across cancer types....
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Oct 28, 2013 |  BioCentury  |  Tools & Techniques

NanoTag, you're it

Genia Technologies Inc. believes its nanopore technology can sequence DNA faster and cheaper than other sequencing technologies without sacrificing accuracy. The key to the technology lies in the detection of four distinct polymer tails called...
07:00 , May 23, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Classification system for endometrial cancers In vitro studies were used to develop a classification system for endometrial cancers that could help guide treatment regimens for patients...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

4Q Financial Markets Preview: Bellwether's ball

For only the second time since 2000, the BioCentury 100 index has matched or beaten the S&P 500 for four consecutive quarters, with most of the gains driven by the bellwether names. Buysiders are cautiously...
07:00 , Sep 10, 2012 |  BioCentury  |  Product Development

Inhibitex's Tox

Bristol-Myers Squibb Co. may have looked past in vitro safety signals in a rush to add Inhibitex Inc. 's nucleoside NS5B polymerase inhibitor to its HCV portfolio. If the pharma was gambling that it could...
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest...